A $100 million package of PBS listings has provided subsidised access to new treatments for melanoma, metastatic bowel cancer and neuroendocrine tumours. Combination treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) has been be listed on the PBS from December 1 for patients with unresectable, stage lll or stage IV malignant melanoma. The July 2018 meeting ...
Already a member?
Enter your email to keep reading.